+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID06609850

Comparing TACE-Lenvatinib With TACE-Lenvatinib Plus Ablation for Intermediate-Stage Recurrent Liver Cancer

Led by Sun Yat-sen University · Updated on 2024-12-03

116

Participants Needed

1

Research Sites

108 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying treatments for intermediate-stage recurrent hepatocellular carcinoma RHCC, a condition where liver cancer returns at a specific stage. This trial compares two approaches a combination of transarterial chemoembolization TACE with the drug Lenvatinib, and the same combination plus ablation therapy. The goal is to determine if adding ablation improves outcomes for patients with this type of liver cancer. The study has two groups. One group receives TACE, where a microcatheter delivers chemotherapy drugs directly to the tumors blood supply, combined with daily oral Lenvatinib doses based on body weight. The other group receives the same TACE and Lenvatinib treatment plus ablation therapy radiofrequency, microwave, or cryoablation performed 6 to 8 weeks after TACE using ultrasound or CT guidance. Success of ablation is measured by achieving an adequate margin beyond the tumor size. Participants will be monitored for at least 24 months to evaluate progression-free survival, with additional follow-up up to 36 months to observe overall survival and tumor response rates. Assessments include imaging and clinical evaluations to track tumor progression and treatment effects. The study aims to identify which patients benefit most from combining ablation with TACE and Lenvatinib, with safety and effectiveness monitored throughout the trial.

CONDITIONS

Brief Title

The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

Research Team

Q

Qunfang Zhou

F

Feng Duan

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here